Background
Somatic mutations in PIK3CA (phosphatidylinositol-4,5-bisphosphonate 3-kinase [PI3K], catalytic subunit alpha gene) activate the PI3K-AKT signaling pathway and contribute to pathogenesis of various malignancies, including colorectal cancer.
Methods
We examined associations of PIK3CA oncogene mutation with relapse, survival, and treatment efficacy in 627 stage III colon carcinoma case subjects within a randomized adjuvant chemotherapy trial (5- [Alliance]). We detected PIK3CA mutation in exons 9 and 20 by polymerase chain reaction and pyrosequencing. Cox proportional hazards model was used to assess prognostic and predictive role of PIK3CA mutation, adjusting for clinical features and status of routine standard molecular pathology features, including KRAS and BRAF mutations and microsatellite instability (mismatch repair deficiency). All statistical tests were two-sided.
Results
Compared with PIK3CA wild-type cases, overall status of PIK3CA mutation positivity or the presence of PIK3CA mutation in either exon 9 or 20 alone was not statistically significantly associated with recurrence-free, diseasefree, or overall survival (log-rank P > .70; P > .40 in multivariable regression models). There was no statistically significant interaction between PIK3CA and KRAS (or BRAF) mutation status in survival analysis (P interaction > .18). PIK3CA mutation status did not appear to predict better or worse response to IFL therapy compared with FU/LV therapy (P interaction > .16).
Conclusions
Overall tumor PIK3CA mutation status is not associated with stage III colon cancer prognosis. PIK3CA mutation does not appear to serve as a predictive tumor molecular biomarker for response to irinotecan-based adjuvant chemotherapy.
J Natl Cancer Inst;2013;105: [1789] [1790] [1791] [1792] [1793] [1794] [1795] [1796] [1797] [1798] Phosphatidylinositol-4,5-bisphosphonate 3-kinase (PI3K) can activate the AKT signaling pathway and facilitate cellular growth, proliferation, and survival (1) . Activating mutations in PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha gene; HGNC ID; HGNC:8975) have been found in various human malignancies, including colon cancers (2) . A subset (10%-30%) of colorectal cancers harbor PIK3CA mutations, which have been associated with various clinical and molecular features, including proximal tumor location and KRAS mutation (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
Despite many previous studies (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) , a prognostic role of overall PIK3CA mutation status in colorectal cancer remains uncertain, although coexistence of PIK3CA mutations in both exons 9 and 20 may be associated with shorter survival (13) . Most of these previous studies were underpowered for robust statistical analysis (mostly with total sample size of less than 500 and 10%-20% frequency of PIK3CA mutation). Therefore, additional studies with a large sample size are needed.
A recent study suggests that PIK3CA mutation in colorectal cancer may serve as a molecular biomarker to predict response to aspirin therapy (25) . Nonetheless, clinical utility of PIK3CA mutation test on colorectal cancer as a predictive tumor biomarker remains to be fully characterized (22, (26) (27) (28) (29) .
We therefore conducted this study to examine prognostic and predictive roles of PIK3CA mutation in stage III colon cancer patients who enrolled in the National Cancer Institute-sponsored randomized clinical trial comparing postoperative adjuvant 5-fluorouracil (FU)/leucovorin (LV) with irinotecan/FU/LV (IFL) (CALGB 89803 [Alliance]) (30) . Because data on postoperative treatment, performance status, and disease stage were carefully recorded in the trial, we could assess prognostic and predictive roles of PIK3CA mutations in colon cancer while controlling for potential confounding by those covariables and key molecular characteristics, including KRAS, BRAF, and microsatellite instability (MSI) status. It is important to consider KRAS, BRAF, and MSI status because these are now routinely assessed in colorectal cancer for patient management.
Methods

Study Population
Patients in this study were participants in the National Cancer Institute-sponsored Cancer and Leukemia Group B (CALGB) phase III adjuvant therapy trial for stage III colon cancer comparing therapy with the weekly Roswell Park regimen of FU/LV with weekly bolus regimen of IFL (CALGB 89803; ClinicalTrials.gov Identifier: NCT00003835) (30) . CALGB is now part of the Alliance for Clinical Trials in Oncology. Between April 1999 and May 2001, 1264 patients were enrolled. Patients in the treatment trial (and thus this companion study) were eligible if they underwent a complete surgical resection of the primary tumor within 56 days before study entry and had regional lymph node metastases but no evidence of distant metastases (ie, stage III). Considering the colorectal continuum model, we included cases from cecal cancers to sigmoid cancers (31) . Moreover, patients were required to have a baseline Eastern Cooperative Oncology Group performance status of 0 to 2 (ambulatory) and have adequate bone marrow, renal, and hepatic function. Cancer staging was based on Tumor Node Metastatis (TNM) classification (http://www.cancer.org). This analysis represents correlative research based on a subset of patients within the trial and was limited to 627 patients for whom archived formalinfixed paraffin-embedded tumor tissue and PIK3CA sequencing data were available. All patients signed informed consent, approved by each site's institutional review board.
We compared baseline characteristics of the patients who were included in this study (with available PIK3CA data: n = 627) with those who were excluded from this study because of unavailability of tissue data (n = 637). We did not detect any statistically significant or substantial difference between these two groups in terms of age, sex, body mass index, family history, tumor location, extent of invasion through bowel wall (pT stage), lymph node involvement (pN stage), performance status, clinical bowel perforation, clinical bowel obstruction, or treatment arm (all P > .05). In addition, recurrence-free (RFS), disease-free (DFS), or overall survival (OS) did not statistically significantly differ in subjects with available PIK3CA data as compared with those without PIK3CA data (multivariable hazard ratio [HR] = 1.05, 95% confidence interval [CI] = 0.87 to 1.27; multivariable HR = 1.10, 95% CI = 0.93 to 1.31; multivariable HR = 1.12, 95% CI = 0.93 to 1.36, respectively).
As part of the quality assurance program of the Alliance, members of the Audit Committee visit all participating institutions at least once every 3 years to review source documents. The auditors verify compliance with federal regulations and protocol requirements, including those pertaining to eligibility, treatment, adverse events, tumor response, and outcome in a sample of protocols at each institution. Such on-site review of medical records was performed for a subgroup of 328 (26%) of the 1264 patients included in the treatment trial. Data quality was also ensured by review of data by the Alliance Statistics and Data Center and by the study chairperson following Alliance policies.
Definitions of Study Endpoints
The study endpoints were 1) RFS, defined as the time from the study enrollment to tumor recurrence or occurrence of a new primary colon cancer; 2) DFS, defined as time from the study enrollment to cancer recurrence, occurrence of a new primary colon cancer, or death from any cause; and 3) OS, defined as the time from the study enrollment to death from any cause. For RFS, patients who died without known cancer recurrence were censored at last documented evaluation by a treating provider.
DNA Extraction From Tumor, PIK3CA, BRAF, and KRAS sequencing and MSI Analysis Tumor molecular analyses were performed blinded to patient and outcome data. DNA was extracted from paraffin-embedded colon cancer tissue (32) . We marked tumor areas on hematoxylin and eosin-stained slides and dissected tumor tissue by a sterile needle. Polymerase chain reaction (PCR) and pyrosequencing targeted for mutation hotspots in PIK3CA exons 9 and 20 (13) , BRAF codon 600 (33) , and KRAS codons 12 and 13 were performed, as previously described (32) , in the laboratory at the Dana-Farber Cancer Institute. Pyrosequencing assay has been found to be more sensitive than Sanger sequencing and can detect approximately 5% to 10% of mutant alleles among a mixture of mutant and normal alleles (32) . MSI was assessed by PCR for 10 microsatellite markers (BAT25, BAT26, D17S250, D5S346, ACTC, D18S55, BAT40, D10S197, BAT34c4, and MycL) (34) . Tumors with instability in 50% or more of the loci were classified as MSI-high, and those with instability in 0% to 49% of the loci were classified as microsatellite stable; and the concordance between MSI testing and immunohistochemistry for MLH1 or MSH2 loss was 97% (34) . For 28 cases without PCR MSI results, those with loss of MLH1 or MSH2 were classified as MSI-high, and those with intact expression of MLH1 and MSH2 were classified as microsatellite stable.
Statistical Analyses
Detailed statistical methods are described in the Supplementary Methods (available online). All analyses were based on the clinical study database frozen on November 9, 2009. SAS version 9.2 (SAS Institute, Cary, NC) was used for all statistical analyses, and all P values were two-sided. Statistical significance was set at P equal to .05 for main hypothesis testing on PIK3CA status and outcome. For exploratory analyses of interactions (between PIK3CA mutation and each of the variables, including age, sex, etc.) and clinical, pathological, and molecular associations, we adjusted statistical significance level by Bonferroni correction to P equal to .004 (.05 divided by 13) to account for multiple hypothesis testing. Because a vast majority of participants were non-Hispanic whites, we did not perform analyses stratified by ethnic group.
The Kaplan-Meier method was used to estimate the distribution of survival time according to PIK3CA status, and the log-rank test was used to compare survival between subgroups. We used the multivariable Cox proportional hazards model to estimate survival hazard ratio according to tumor PIK3CA status. We conducted power calculations for survival analyses (Supplementary Table 1 , available online). The proportionality of hazards assumption was assessed using standard survival plots and by evaluating a timedependent variable, which was the cross-product of PIK3CA and (54) 303 (55) 15 (31) 18 (72) 34 (46) Female 290 (46) 250 (45) 33 (69) 7 (28) 40 (54) Age, y, mean ± SD 140 (29) 19 (42) 3 (15) 22 (33) 25-29
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Wild-type 376 (65) 335 (66) 24 (50) 17 (71) 41 (56) Mutant 203 (35) 171 (34) 24 (50) 7 (29) 32 (44) ( Table continues) survival time (P = .46 for RFS; P = .76 for DFS; P = .35 for OS). To assess the potential differential effect of treatment arm according to PIK3CA status, we performed a single multivariable Cox regression analysis, in which we could estimate the effect of treatment arm simultaneously in two strata of PIK3CA status, using a reparameterization of the interaction term(s) (35) . Interaction was also assessed by including the cross-product of PIK3CA and another variable of interest (without data-missing cases) in a multivariable model using the Wald test.
results
PIK3CA Mutation and Patient Survival in Stage III Colon Cancer
Study participants were drawn from a multicenter study of postoperative adjuvant chemotherapy in stage III colon cancer patients who underwent a curative-intent surgical resection (CALGB 89803) (30) . We included 627 case subjects in this study based on availability of tumor tissue for sequencing of PIK3CA exons 9 and 20, which detected mutation in 74 (12%) patients. One case subject showed mutations in both exons 9 and 20. Table 1 summarizes baseline characteristics according to PIK3CA mutation status.
Overall prevalence of postdiagnosis regular aspirin use (defined as two or more tablets per week) was 7.2% (n = 45 of 627 patients), and there were only four patients who had PIK3CA-mutated tumor and regularly used aspirin after colon cancer diagnosis.
With median follow-up of 7.6 (interquartile range = 7.1-8.1) years among those who were censored for overall survival outcome, there were 225 events for RFS analysis, 258 events for DFS analysis, and 210 events for OS analysis.
In a Kaplan-Meier analysis (Figure 1 ), compared with PIK3CA wild-type patients, PIK3CA mutation in either exon 9 or 20 was not statistically significantly associated with RFS, DFS, or OS outcome (log-rank P > .70).
In multivariable Cox regression analysis, we examined the prognostic association of PIK3CA mutation adjusting for other predictors of patient survival (Table 2; Supplementary Table 2 , available online, shows data on all variables in the final multivariable models). Compared with PIK3CA wild-type cases, PIK3CA mutation in only exon 9, or only exon 20, or overall PIK3CA mutation status was not statistically significantly associated with RFS, DFS, or OS outcome in univariate or multivariable analysis (P > .40 in multivariable regression models). Multivariable hazard ratios for RFS, DFS, and OS in overall PIK3CA mutated tumors compared with PIK3CA wild-type tumors were 0.84 (95% CI = 0.54 to 1.29), 0.92 (95% CI = 0.62 to 1.35), and 0.95 (95% CI = 0.63 to 1.45), respectively.
PIK3CA Mutation and Prognosis in Strata of Combined KRAS and BRAF Status
We assessed a prognostic role of PIK3CA mutation in strata of combined KRAS and BRAF status to examine possible effect modification by KRAS or BRAF status on PIK3CA mutation (Table 3) . We did not observe statistically significant effect modification by KRAS status. The number (n = 6) of cases with both PIK3CA and BRAF mutations precluded robust assessment of effect modification by BRAF status. There was no statistically significant interaction (51) 282 (51) 26 (54) 11 (44) 37 (50) IFL 308 (49) 271 (49) 22 (46) 14 (56) 37 (50) * The percentages indicate the proportion of tumors with a specific clinical or molecular feature among tumors with specific PIK3CA status. There were cases with missing value/status for some of the variables. A χ 2 test was used to assess associations, and all P values were two-sided. FU/LV = 5-fluorouracil and leucovorin; IFL = irinotecan, 5-fluorouracil and leucovorin; SD = standard deviation. † One case subject with PIK3CA mutations in both exons 9 and 20 was excluded. ‡ This category includes one case subject with mutations in both exons 9 and 20. § For 29 cases without MSI results by polymerase chain reaction, those with loss of MLH1 or MSH2 were classified as MSI-high, and those with intact expression of MLH1 and MSH2 as microsatellite stable because concordance between MSI polymerase chain reaction and immunohistochemistry for MLH1 and MSH2 was very high (97%) among case subjects with both results available (34). 
Predictive Role of PIK3CA Mutation for IFL-Based Therapy
We assessed the prognostic role of PIK3CA mutation within each treatment arm and the effect of treatment according to PIK3CA status (Table 4 ). In either treatment arm, PIK3CA mutation was not statistically significantly associated with RFS, DFS, or OS outcome. Multivariable hazard ratios for DFS in PIK3CA mutant tumors compared with PIK3CA wild-type tumors were 0.75 (95% CI = 0.43 to 1.31) among the FU/LV arm and 1.13 (95% CI = 0.65 to 1.96) among the IFL arm.
In either stratum of patients with PIK3CA mutated or wild-type tumors, IFL treatment was not statistically significantly associated with RFS, DFS, or OS outcome compared with FU/LV treatment (Table 4) , and there was no statistically significant interaction between treatment arm and PIK3CA status (P interaction > .16). Multivariable hazard ratios for DFS in the IFL treatment group compared with the FU/LV treatment group were 0.88 (95% CI = 0.68 to 1.15) among the PIK3CA wild-type subtype and 1.33 (95% CI = 0.64 to 2.78) among the PIK3CA mutant subtype.
Interaction Analysis Between PIK3CA and Other Variables
In exploratory analyses, we further examined whether prognostic association of PIK3CA mutation was modified by any other variables, including clinical features and MSI status. We did not observe statistically significant or appreciable effect modification by any of the variables examined for RFS, DFS, or OS outcomes (all P interaction > .04; given multiple hypothesis testing, a P value for statistical significance was adjusted to P = .004).
Discussion
In this study, we found that tumor PIK3CA mutation was not statistically significantly associated with recurrence or survival among more than 600 stage III colon cancer patients, who participated in the randomized trial comparing postoperative IFL with FU/LV (CALGB 89803). We found no evidence for a predictive role of PIK3CA mutation status in IFL-based treatment.
It is a challenge to optimize treatment decision-making for patients with colon cancer because of heterogeneity of colon cancer with regard to both biology and clinical response (36) . Heterogeneity exists in tumors with different mutations, even in one oncogene such as KRAS (37, 38) , and treatment and other host factors can influence (or can be influenced by) tumor characteristics through tumor microenvironment (and vice versa) (39-43). * The multivariable Cox proportional hazards regression model included the same set of covariables that were selected in the final models of the analyses in Table 2 , except for stratifying variables KRAS and BRAF mutation status. Cases with mutations in both KRAS and BRAF were excluded. CI = confidence interval; HR = hazard ratio. Therefore, studies examining tumor biomarkers and clinical outcome are crucial in colon cancer research (44) (45) (46) (47) (48) (49) .
Although previous studies (34, (50) (51) (52) (53) (54) (55) have assessed potential predictive roles of germline genetic or tumor tissue markers for IFL-based chemotherapy, no biomarker has been proven to be useful in predicting response or resistance to IFL-based therapy (54) . A previous analysis of patients in the clinical trial studied in this report suggested that MSI-high might predict an improved patient outcome for treatment with IFL relative to FU/LV (34); however, an independent trial of more than 1200 case subjects comparing IFL vs FU/LV failed to prove a predictive value of MSI status (53) . Additional studies are necessary to identify and validate predictors for IFL-based chemotherapy against colorectal cancer.
Several other predictive roles for PIK3CA mutation in colorectal cancer have been examined (22, (26) (27) (28) 56) . A recent study (25) suggests that PIK3CA mutation in colorectal cancer may predict response to aspirin treatment, and this finding appears to be replicated (56) . Challenges include relatively low prevalence (10%-20%) of PIK3CA mutations, possible differential effects of exon 9 and 20 mutations, and potential confounding effect by associated KRAS mutations. A meta-analysis suggested that PIK3CA exon 20 mutation in metastatic colorectal cancer may predict response to anti-EGFR therapy (57) . Finally, a recent preclinical study suggested that PIK3CA mutant colorectal cancer may respond to the SRC inhibitor saracatinib (58). Thus, it is possible that PIK3CA mutation status may serve as a predictive biomarker for a number of different therapeutic agents and their combinations, which include aspirin and other drugs. Additional large-scale trials are needed to define predictive roles of PIK3CA mutations in colorectal cancer.
Studies have examined the prognostic significance of PIK3CA mutations in colorectal cancer (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Although two studies linked tumor PIK3CA mutation to poor prognosis (10, 17) , statistical power in these reports was limited (each total sample size was less than 160). In one study (n = 586) (6), the presence of a mutation in any one of KRAS, BRAF, and PIK3CA oncogenes was associated with inferior prognosis; however, this could be purely because of the effects of BRAF mutations (59) (60) (61) (62) . Two other studies showed that PIK3CA exon 20 mutations were associated with poor prognosis, whereas PIK3CA exon 9 mutations were not associated with prognosis (20, 23) . Other reports showed that PIK3CA mutations were associated with neither distant metastasis to liver (63) nor patient survival (11, 12, 21) . The two largest prognostic studies [n = 2091 (14) , and n = 1170 (13)] did not support a prognostic role of overall PIK3CA mutation status. In our analysis, neither PIK3CA overall mutation status nor PIK3CA mutation in exon 9 or 20 alone was statistically significantly associated with tumor recurrence or overall survival. Our study further underscores the importance of large, multicenter, collaborative studies; it should be noted that small, underpowered studies with null findings experience higher likelihood of being unwritten and unpublished when compared with small studies with "statistically significant" results. Well-designed, large-scale studies with appropriate statistical power can be published irrespective of positive or null findings, hence being less susceptible to "publication bias." Thus, more weight should be placed on the data from large-scale studies upon evaluation of published data on the prognostic significance of tumor biomarkers (13). * The multivariable Cox proportional hazards regression model included the same set of covariables that were selected in the final models of the analyses in Table 2 . CI = confidence interval; FU/LV = 5-fluorouracil and leucovorin; HR = hazard ratio; IFL = irinotecan, 5-fluorouracil and leucovorin. † Interaction was assessed by including the cross-product of PIK3CA and treatment arm variables in a multivariable model, and the Wald test was used. All P values are two-sided.
Interestingly, Liao et al. (13) demonstrated that the coexistence of PIK3CA mutations in both exons 9 and 20 was associated with shorter survival. Experimental evidence suggests that PIK3CA helical and kinase domain mutations differentially activate protein function and that the presence of PIK3CA mutations in both exon 9 and exon 20 results in a synergistic gain of enzymatic function (64) . However, in our analysis, there was only one case subject with PIK3CA mutations in both exons 9 and 20, which precluded robust outcome assessment.
A ligand-receptor interaction of EGFR (HGNC ID: HGNC:3236) leads to activation of two main signal transduction pathways, RAS-RAF-MAPK and PI3K-AKT. Activating mutations in KRAS, BRAF, and/or PIK3CA are well-known carcinogenic mechanisms, and there may be interactive effects of KRAS and PIK3CA mutations (65) . In our study on colon cancer, we did not observe statistically significant interactive effects of PIK3CA and KRAS (or BRAF) mutations.
This study used the multi-institutional clinical trial of adjuvant chemotherapy and had several strengths. All study subjects were stage III cancer patients, which decreased potential residual confounding by disease stage. Methods of follow-up and treatment were standardized, and the date and nature of recurrence were recorded. Furthermore, integrative database of treatment, behavioral and lifestyle factors, tumor molecular characteristics (including PIK3CA, KRAS, BRAF, and MSI status), and clinical outcomes enable molecular pathological epidemiology research (66, 67) and controlling for confounding by lifestyle factors. The paradigm of molecular pathological epidemiology has been widely used (68) (69) (70) (71) (72) (73) (74) (75) (76) . In colorectal cancer, KRAS, BRAF, and MSI tests are a part of routine clinical practice (77) , and PIK3CA test is an emerging clinical test (25, 29, 56) .
We recognize limitations of our study. Patients who enrolled in the clinical trials constituted a selected group of individuals and might differ from the general population. Patients needed to meet enrollment criteria and be motivated to participate and were further selected based on availability of tissue specimens. Nonetheless, demographic, clinical, or prognostic data of the patients selected in this study did not substantially differ from those without available tumor tissue. Because this trial included patients from both academic and community hospitals across the United States and Canada, our results might reflect stage III colon cancers in the general North American population. Finally, because PIK3CA status was not available on all patients, statistical power was attenuated, especially for predictive assessment for response to IFL use.
In conclusion, our current study of stage III colon cancer patients has shown that tumor PIK3CA mutation is not statistically significantly associated with recurrence or survival and that PIK3CA mutation status is not a predictive marker for response to IFL-based chemotherapy. Additional large-scale studies are needed to define predictive roles of PIK3CA mutations in colon cancer. 
